Cairo-based pharmaceutical giant EIPICO has delivered stellar results, crushing its 2023 goals with sales surpassing EGP 5 billion. The company reported export revenues of $54 million, capturing 26% of Egypt's total pharmaceutical exports and dominating 30% of Africa-bound shipments. With a production volume of EGP 5.6 billion and EGP 3.8 billion invested in facility upgrades, EIPICO is charging ahead. Chairman Ahmed Kelani unveiled bold 2024 plans: EGP 800 million in new investments and a revenue target of EGP 6.5 billion, fueled by domestic and export growth. Net profits soared 54% year-on-year to EGP 644 million in the first nine months of 2023, signaling strong momentum.